BioPlus Co. Ltd.

As of June 30, 2026, BioPlus Co. Ltd. carries a market capitalization of 256.93B, placing it among publicly traded companies globally. Its enterprise value stands at 315.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioPlus Co. Ltd.'s next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, BioPlus Co. Ltd. has 61.54M shares outstanding.

As of June 30, 2026, BioPlus Co. Ltd. trades at a trailing price-to-earnings ratio of 18.36. The price-to-sales ratio is 2.56, and the price-to-book ratio stands at 1.44.

As of June 30, 2026, BioPlus Co. Ltd. trades at an EV/EBITDA multiple of 14.16 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 17.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 315.13B versus a market cap of 256.93B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioPlus Co. Ltd. maintains a current ratio of 0.95, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.77, indicating elevated leverage, while an interest coverage ratio of 73.70 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioPlus Co. Ltd. posted a return on equity (ROE) of 8.32, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.88, measuring how efficiently the asset base is converted into earnings. The company generates approximately 553.92M in revenue per employee across its workforce of 179.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times BioPlus Co. Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioPlus Co. Ltd. recorded an income tax benefit of -2.30B rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 17.49B, leaving 13.85B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BioPlus Co. Ltd.'s stock has declined approximately 44.14% over the past 52 weeks. The 50-day moving average sits at 3,490.80, while the 200-day moving average is 4,574.15.

Over the twelve months ended June 30, 2026, BioPlus Co. Ltd. generated 99.15B in revenue and converted that into 13.85B in net income, yielding earnings per share of 309.90. EBITDA reached 22.25B, while operating income came in at 17.74B.

As of June 30, 2026, BioPlus Co. Ltd. holds 29.35B in cash and equivalents against 65.65B in total debt, resulting in a net debt position of 43.97B. Total book value stands at 178.44B, with working capital of -3.76B providing operational flexibility.

BioPlus Co. Ltd. produced 14.32B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.09B in capital expenditures, free cash flow totaled -5.77B - equivalent to -94.83 per share.

Over the twelve months ended June 30, 2026, BioPlus Co. Ltd. posted a gross margin of 68.66, reflecting its pricing power and cost economics. The operating margin of 17.89 and net profit margin of 13.96 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.17: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.88, meaning BioPlus Co. Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BioPlus Co. Ltd.'s most recent stock split took place on November 23, 2022 with a 1:4 split ratio.

As of June 30, 2026, BioPlus Co. Ltd. has an Altman Z-Score of 2.60, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.